Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study.

ABSTRACT:

Introduction

Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consistent with the global ALEX study. We present updated data after more than or equal to 5 years of follow-up from the "last patient in" date.

Methods

Adult patients with treatment-naïve, advanced ALK-positive NSCLC from mainland China, South Korea, and Thailand were randomized 2:1 to receive twice-daily 600 mg alectinib (n = 125) or 250 mg crizotinib (n = 62). The primary endpoint was investigator-assessed progression-free survival. Secondary or exploratory endpoints included overall survival, objective response rate, t

SUBMITTER: Zhou C 

PROVIDER: S-EPMC11399573 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature